US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

UK contract research organization hVIVO (AIM: HVO) is gearing up to test an inhaled antiviral candidate, IN-002, for ...

Inhalon Biopharma, Inc. (Inhalon), a clinical-stage company advancing a first-in-class inhaled antibody platform for treating acute respiratory infections (ARI), today announced the completion of ...

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

L'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.

HC Wainwright reaffirmed their buy rating on shares of Vir Biotechnology (NASDAQ:VIR – Free Report) in a research report report published on Friday morning,Benzinga reports. They currently have a $110 ...

A memorandum issued to federal government agencies has led to the scrubbing of websites with critical public health ...

What you need to know ### BMJ Learning To obtain accredited continuous professional development points, subscribers to BMJ Learning can complete the full module at The module contains seven ...

K92 Mining Inc. ("K92" or the "Company") announces that it will release its 2024 fourth quarter financial results before the North American trading markets open on Monday, March 17, 2025. Conference ...

Margie Danchin, Professor of Paediatrics and vaccinologist, Royal Childrens Hospital, University of Melbourne and Murdoch Childrens Research Institute (MCRI); Associate Dean International, University ...